$Moderna, Inc.(MRNA)$ $Moderna, Inc.(MRNA)$ Barclays sees a scenario where shares could trade to roughly $400 if intismeran succeeds in renal cell carcinoma (RCC), though that's conditional versus its official lower target. After ESMO discussions in Madrid, Barclays noted that management and physicians sounded confident about success in adjuvant RCC and muscle-invasive bladder cancer. The note also points to Phase 2b data expected in late 2026/early 2027 for RCC and 2027 for bladder. Those readouts could materially reshape the valuation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
